The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation For Parkinson’s Disease- Biology, 2025(SUPPLEMENT) Validation of LRRK2 Modifiers as Potential PD Therapeutic Targets
-
Research Grant, 2025Applying the Neuronal Alpha-synuclein Disease Integrated Staging System in Multiple System Atrophy
Study Rationale: The neuropathological hallmark feature of Parkinson’s disease (PD) is the accumulation of a misfolded protein called alpha-synuclein in neurons, which qualifies PD as a neuronal...
-
Research Grant, 2025(SUPPLEMENT) Enhancing Brain Clearance Mechanisms to Limit Parkinson Disease Progression
Study Rationale: Recent evidence has shown that people with Parkinson’s disease have a buildup of toxic proteins in their brains, as a result of impaired waste clearance mechanisms. Linked to this...
-
Research Grant, 2025Clinical Evaluation of 18F-FD4 as a Potential Alpha-synuclein PET Imaging Biomarker
-
iPSC Phenotyping Environmental Exposure Program, 2025Assessing PD-relevant Toxicants on Neurons and Microglia and their Crosstalk
Study Rationale: We know that genetics plays a role in risk of Parkinson’s disease (PD) but does not explain every case, leading to the suggestion that genes work within the context of other exposures...
-
Seed Amplification Assay Innovation Program, 2025Quantitative SAA for Measuring Disease Progression in Parkinson’s Disease from Plasma
Study Rationale: Parkinson’s disease (PD) is associated with the accumulation of clumped alpha-synuclein (asyn) protein in the brain. Detecting asyn in blood plasma could provide a less invasive and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.